Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival

Nitti, Donato; Belluco, Claudio; Montesco, Maria Cristina; Bertorelle, Roberta; Pian, P. P. Da; Fassina, Ambrogio; Ninfo, Vito; Chieco‐Bianchi, Luigi; Lise, Mario

doi:10.1016/s0959-8049(97)10165-4

Cited by 30 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No significant correlation between p53 immunoreactivity and prognosis was observed, although the authors suggested a trend (P Ͻ 0.08) for mutated p53 to predict a worse outcome compared with wild type p53, a trend that was reported as statistically significant in a later study. 45 The explanation for the discrepancy between previous studies 44,45 and the current report is unclear, although the same antibody was used by Pocard et al 44 that was applied by us. During the preparation of this article, De Jong et al 46 reported circumstantial evidence, based on immunohistochemical analyses in 38 patients who underwent liver resection for colorectal metastases, supporting our p53 DNA sequence data.…”

Section: Discussioncontrasting

confidence: 59%

P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection

Yang¹,

Forslund²,

Remotti³

et al. 2001

Cancer

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 59%

P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection

Yang¹,

Forslund²,

Remotti³

et al. 2001

Cancer

View full text Add to dashboard Cite

“…Bellucco et al [127] showed a lower median survival among patients with p53-positive tumors with synchronous unresectable CRLM treated by hepatic artery infusional chemotherapy. These data were later confirmed in patients undergoing curative hepatic resection for CRLM, as p53 protein status was the single best predictor of survival (median survival: p53 wild type, 93 mo vs p53 mutated 27 mo) [128] . Similarly, 3-and 5-year survival were better among patients with p53 wild type CRLM [128] .…”

Section: Thymidylate Synthasementioning

confidence: 79%

“…These data were later confirmed in patients undergoing curative hepatic resection for CRLM, as p53 protein status was the single best predictor of survival (median survival: p53 wild type, 93 mo vs p53 mutated 27 mo) [128] . Similarly, 3-and 5-year survival were better among patients with p53 wild type CRLM [128] . Tanaka et al [129] also showed that mutated p53 remained an independent prognostic factor for worse survival after hepatectomy based on a multivariate analysis.…”

Section: Thymidylate Synthasementioning

confidence: 79%

“…Not reported TLI High TLI independently Predicted decreased DFS (P = 0.035) Nitti et al [128] 69 64 p53 Independent predictor of poor survival (RR = 2.53, P = 0.008) Mehta et al [144] 50 30 FGA A high FGA is an independent predictor of survival (P = 0.01) Shimomura et al [136] transfers signals from the cell membrane via the cytoplasm into the nucleus. The ras gene products activate proteins in the Raf family, which consists of the ARAF, BRAF and RAF-1 members [102] .…”

Section: Kras Brafmentioning

confidence: 99%

See 1 more Smart Citation

Surgery for colorectal liver metastases: The evolution of determining prognosis

Spolverato

Ejaz

Azad

et al. 2013

WJGO

View full text Add to dashboard Cite

Despite improvements in the multi-modality treatment of colorectal liver metastasis (CRLM), survival after resection remains varied. Determining prognosis after surgical resection has historically been predicated on preoperative clinicopathological factors such as primary tumor stage, carcinoembryonic antigen levels, number of liver metastases, presence of extrahepatic disease, as well as other factors. While scoring systems have been developed by combining certain preoperative factors, these have been inconsistent in accurately determining prognosis. There has been increasing interest in the use of biologic and molecular markers to predict prognosis following CRLM. The role of markers such as KRAS, BRAF, p53, human telomerase reverse transcriptase, thymidylate synthase, Ki-67, and hypoxia inducible factor-1α and their correlation with accurately predicting survival after surgical resection have been supported by several studies. Furthermore, other elements such as pathological response to chemotherapy and the presence of circulating tumor cells have shown promise in accurately determining prognosis after resection for colorectal liver metastasis. We herein review past, present, and possible future markers of prognosis among colorectal cancer patients with liver metastasis undergoing resection with curative intent.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Colorectal; Metastasis; Prognosis; Risk score; Molecular markers; Outcomes Core tip: Historically, prognosis after resection has been largely assessed based on preoperative clinicopathologic features. Data validating the prognostic value of patient and tumor specific factors have been mixed, with many recent studies showing these scoring systems to correlate poorly with survival. Rather, there has been an emerging interest in biological or molecular markers of prognosis to more effectively assess patient prognosis after resection of colorectal liver metastasis. In this review, we discuss past, present, and possible future markers of prognosis among colorectal cancer patients with liver metastasis undergoing resection with curative intent.

show abstract

“…114 In fact, some investigators have suggested that molecular tumor biomarkers may be more useful than many traditional clinicopathologic factors at predicting survival after resection of hepatic colorectal metastases. [114][115][116][117][118][119] Specifically, proliferation markers such as Ki-67 labeling index 116,119,120 (also see p. 53 in De Jong et al 121 ), and human telomerase reverse transcriptase expression, 114,119 tritiated thymidine uptake, 122 and thymidylate synthase expression 118 have been shown to be more powerful predictors of recurrence and survival. These data serve to emphasize that traditional preoperative clinicopathologic factors are inadequate when attempting to define the true underlying biology of colorectal metastases.…”

Section: Major Indicators Of Prognosismentioning

confidence: 99%

Surgical Therapy for Colorectal Metastases to the Liver

Pawlik

Choti

2007

Journal of Gastrointestinal Surgery

205

118

View full text Add to dashboard Cite

Colorectal cancer is the fourth most common type of cancer in the West and the second leading cause of cancer-related deaths in the United States. Approximately 35 to 55% of patients with colorectal cancer develop hepatic metastases during the course of their disease. Surgical resection of colorectal liver metastases represents the only chance at potential cure, and long-term survival can be achieved in 35 to 58% of patients after resection. The goal of hepatic resection should be to resect all metastases with negative histologic margins while preserving sufficient functional hepatic parenchyma. In patients with extensive metastatic disease who would otherwise be unresectable, ablative approaches can be used instead of or combined with hepatic resection. The use of portal vein embolization and preoperative chemotherapy may also expand the population of patients who are candidates for surgical treatment. Despite these advances, many patients still experience a recurrence after hepatic resection. More active systemic chemotherapy agents are now available and are being increasingly employed as adjuvant therapy either before or after surgery. Modern treatment of colorectal liver metastasis requires a multidisciplinary approach in an effort to increase the number of patients who may benefit from surgical treatment of colorectal cancer liver metastasis.

show abstract

Nuclear p53 protein expression in resected hepatic metastases from colorectal cancer: an independent prognostic factor of survival

Cited by 30 publications

References 45 publications

P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection

P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection

Surgery for colorectal liver metastases: The evolution of determining prognosis

Surgical Therapy for Colorectal Metastases to the Liver

Contact Info

Product

Resources

About